Vigil Neuroscience, Inc.

NasdaqGS VIGL

Vigil Neuroscience, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -4,548.76%

Vigil Neuroscience, Inc. EBITDA Margin is -4,548.76% for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: VIGL

Vigil Neuroscience, Inc.

CEO	Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
IPO Date	Jan. 7, 2022
Location	United States
Headquarters	1 Broadway
Employees	64
Sector	Healthcare
Industries Biotechnology 3D Printing Artificial Intelligence (AI) Clinical Trials Pharmaceuticals Robotics Vaccines

Description

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years